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Reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation is increasingly considered
for patients with chronic lymphocytic leukemia (CLL). To investigate the impact of in vivo T cell depletion
with alemtuzumab on the incidence of graft-versus-host disease (GVHD), nonrelapse mortality (NRM),
progression-free survival (PFS), and overall survival (OS), we retrospectively analyzed the outcomes of 62
consecutive CLL patients conditioned with fludarabine and melphalan at 4 institutions. For GVHD prophy-
laxis, 41 patients (cohort 1) received alemtuzumab and cyclosporin; and 21 patients (cohort 2) received
cyclosporin plus methotrexate or mycophenolate. Donors were 50 siblings and 12 unrelated volunteers.
Twenty-two (36%) patients received donor lymphocyte infusions (DLI), 20 (49%) from cohort 1 and 2
(10%) from cohort 2 (P5.002). Grade III-IV acute GVHD (aGVHD) was observed in 20% and 38% of patients
from cohorts 1 and 2, respectively (P 5 .14). Extensive chronic GVHD (cGVHD) was observed in 10% and
48% of patients from cohorts 1 and 2, respectively (P5.03). Therewas a trend toward a higher viral infection
rate in cohort 1 compared to cohort 2 (68% versus 43%, P 5 .062), but the incidence of cytomegalovirus
(CMV) reactivation was not significantly different. The 3-year OS, PFS, NRM, and relapse rates were 65%,
39%, 28%, and 32%, respectively, for cohort 1; and 57%, 47%, 34%, and 20%, respectively, for cohort 2
(P5.629, P5.361, P5.735, and P5 0.112, respectively). In conclusion, both methods of GVHD prophylaxis
were equivalent in terms of survival. The administration of alemtuzumab led to reduced cGVHD, possibly
improving quality of life.
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AlemtuzumabINTRODUCTION
B cell chronic lymphocytic leukemia (CLL) is
a complex disease characterized by a variable clinical
course. A group of patients have an aggressive disease,
From the 1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;
2Birmingham Heartlands Hospital, Birmingham, United King-
dom; 3Royal Free & University College Hospitals, London,
United Kingdom; and 4Hospital Clinico Universitario, Sala-
manca, Spain.
Correspondence and reprint requests: Julio Delgado, MD, PhD,
Servei d’Hematologia Clinica, Hospital de la Santa Creu i Sant
Pau, C/Sant Antoni Maria Claret 167, 08025 Barcelona, Spain
(e-mail: jdelgadog@santpau.cat).
Received June 17, 2008; accepted September 2, 2008
1083-8791/08/1411-0001$34.00/0
doi:10.1016/j.bbmt.2008.09.001requiring treatment very early after diagnosis, whereas
others have an indolent evolution and may not need
any kind of therapy for many years [1]. A better under-
standing of its heterogeneity has emerged from studies
defining new prognostic factors such as CD38 expres-
sion, ZAP-70 positivity, cytogenetic abnormalities,
and immunoglobulin heavy chain variable region
(IgVH) mutations [2].
It is nevertheless recognized that most CLL
patients, including around 50% of those with early-
stage disease, will eventually die of disease progres-
sion or disease-related complications [3]. In addition,
up to 30% of patients are younger than 65 years [4],
and they almost invariably die of their disease [5].
In some of these patients, sustained responses have
been obtained with allogeneic hematopoietic cell
transplantation (allo-HCT) following conventional
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with chemosensitive disease at transplantation [6].
Unfortunately, myeloablative transplantation is only
suitable for a small proportion of young patients
and is hampered by a nonrelapse mortality (NRM)
approaching 50% [7]. Reduced-intensity condition-
ing (RIC) regimens were devised to reduce NRM
and extend the use of allo-HCT to older patients or
those with other medical comorbidities [8]. As such,
this procedure is increasingly considered as a thera-
peutic option for patients with advanced CLL and
other lymphoid malignancies [9,10].
There are several RIC regimens, but the majority
contain fludarabine (Flu) plus an alkylating agent, usu-
ally melphalan (Mel), busulfan (Bu), or cyclophospha-
mide (Cy) [11]. The Spanish Collaborative Group has
relied on the Flu-Mel combination for lymphoid
malignancies, using cyclosporin plus methotrexate or
mycophenolate mofetil for graft-versus-host disease
(GVHD) prophylaxis [12]. The UK Collaborative
Group scheme, on the other hand, adds the anti-
CD52 monoclonal antibody (mAb; alemtuzumab;
Campath-1H) to the Flu-Mel combination to deplete
recipient and incoming donor T cells, providing sus-
tained engraftment while reducing the incidence of
GVHD [13]. This reduced GVHD rate is, however,
counterbalanced by a delayed post-HCT immune re-
constitution, which potentially increases the risk of se-
vere infections and impairs the graft-versus-leukemia
(GVL) effect [14].
We report 62 consecutive CLL patients who un-
derwent RIC allo-HCT at 4 different institutions: 2
in Spain, and 2 in the United Kingdom. Patients
treated in Spain received a standard Flu-Mel condi-
tioning regimen, whereas patients treated in the
United Kingdom had alemtuzumab added to Flu and
Mel. The aim of the study was to assess the effect of
alemtuzumab on GVHD and NRM rates as well as
progression-free survival (PFS) and overall survival
(OS) in both cohorts.
PATIENTS AND METHODS
Study Patients
We retrospectively collected data from 62 consec-
utive patients with advancedCLLwho underwent RIC
allo-HCT using a Flu-Mel conditioning regimen from
1999 to 2007. The Ethics Committee of each partici-
pant center approved all study protocols, and all pa-
tients and donors gave written informed consent.
Eligibility criteria for transplantation varied across all
4 institutions, but the procedure was generally offered
to younger patients with chemorefractory disease,
early relapse, and/or poor risk cytogenetic abnormali-
ties, who had a suitable donor. Eighteen patients from
the UK were included in the Campath De-escalationProtocol, which analyzed the effect of alemtuzumab
dose reduction on the incidence of GVHD and infec-
tious complications. Six patients treated in Spain were
recruited for the TIRCAMPATH-Alo-2002 clinical
trial, which randomly allocated patients with lympho-
proliferative disorders undergoing RIC allo-HCT
to Flu-Mel or Flu-Mel-alemtuzumab conditioning
regimen.
Fluorescein in situ hybridization (FISH) cytoge-
netic studies and analysis of the mutation status of
the immunoglobulin gene were performed using
conventional methods as previously described [15].
Patients were excluded if they were older than 70 years,
the left ventricular ejection fraction was\40%, creat-
inine clearance was \30 mL/min per 1.73 m2, or
serum bilirubin level or liver transaminases were .3
times the upper limit.
Conditioning Regimen, GVHD Prophylaxis, and
Stem Cell Source
The conditioning regimen comprised Flu 30 mg/
m2 daily from days 27 to 23 (total dose, 150 mg/
m2), and Mel 140 mg/m2 on day22. For GVHD pro-
phylaxis, 40 patients received alemtuzumab (20-100
mg) and cyclosporine (cohort 1); and 21 patients re-
ceived cyclosporine plus MTX or mycophenolate mo-
fetil (MMF; cohort 2). The standard alemtuzumab
dose for cohort 1 was 20 mg/day from days 28 to
24 (total dose, 100mg). However, 18 patients received
a total dose of 60mg (8 patients), 40 mg (3 patients), 30
mg (2 patients), and 20 mg (5 patients) alemtuzumab
on days22 and21 as part of the Campath De-escala-
tion Protocol (see Study Patients section).
Cyclosporin was administered at 3 mg/kg daily
starting on day 21. Patients in cohort 2 whose donor
was an HLA-identical sibling were also given MTX
15 mg/m2 on day 11 and 10 mg/m2 on days 13 and
16 in addition to cyclosporin. Patients in cohort 2 re-
ceiving an allograft from an unrelated donor were
givenMMF 15 mg/kg/day twice daily from day11 in-
stead of MTX. Two patients in cohort 2 allografted
from single-locus mismatched unrelated donors were
given antithymocyte globulin (ATG; 2 mg/kg/day
from days 24 to 21) in addition to cyclosporin and
MMF. In the absence of GVHD, cyclosporin 6
MMF were tapered from 3 months after transplanta-
tion. Acute and chronic GVHD (aGVHD, cGVHD)
were graded according to standard criteria [16,17]. In
particular, extensive cGVHD was defined as either
(1) generalized skin involvement; (2) localized skin in-
volvement, and/or liver dysfunction plus involvement
of 1 other target organ; or (3) involvement of at least
2 target organs. Steroid-refractoryGVHDwas defined
as no response to corticosteroids (eg prednisone 2 mg/
kg or equivalent) administered for at least 5 consecu-
tive days or progression after 48 hours of therapy.
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cells (PBSC) from HLA-matched siblings (n 5 50)
or unrelated donors (n 5 12). Patients and their
donors were matched for HLA-A, -B, -C, -DRB1,
and -DQB1 by intermediate- or high-resolution
DNA-typing techniques, as appropriate. Six unrelated
donor/recipient pairs had single-allele mismatches.
Chimerism, Donor Lymphocyte Infusions (DLI),
and Supportive Care
Whole blood and lineage-specific chimerism (in T
cell and myelogenous lineages) were assessed bymeans
of polymerase chain reaction (PCR) analysis of infor-
mative minisatellite regions or FISH for X and Y
chromosomes in the event of sex-mismatched trans-
plantations. Mixed chimerism was defined as the pres-
ence of more than 5% and\95%CD31 cells from the
donor. Patients who had mixed chimerism or residual
disease 6 months after transplantation were eligible to
receive donor lymphocyte infusions (DLI) if there
was no evidence of active GVHD. Escalating doses
of CD31 lymphocytes were administered starting at
a dose of 1 106 T cells/kg. Increasing doses were ad-
ministered at 3-month intervals (3  106, 1  107, 3 
107, and 1 108 T cells/kg) in the absence of GVHD if
mixed chimerism or residual disease persisted.
Infection prophylaxis varied across all participat-
ing centers but included antifungals (fluconazole,
itraconazole, or voriconazole), aciclovir and cotrimox-
azole, or pentamidine. Patients with persistent fever
during neutropenia were treated with broad-spectrum
antibiotics. Additional agents (glycopeptides, amino-
glycosides, antifungals, or antivirals) were added as
clinically indicated. Patients were not routinely
screened for Epstein-Barr virus (EBV) reactivation.
Patients at risk for cytomegalovirus (CMV) reactiva-
tion were monitored weekly by antigenemia or quanti-
tative PCR.When the CMVPCRwas positive, the test
was repeated and preemptive treatment with ganciclo-
vir or its alternatives (valganciclovir, foscarnet) was
started if the result was confirmed.
Definitions and Statistical Analysis
Disease response was evaluated using National
Cancer Institute Working Group (NCI-WG) criteria
[18]. Flu-refractory CLL was defined as disease that
failed to respond to Flu-based therapy or progressive
disease within 6 months of response to a Flu-based
regimen. Where possible, patients in complete remis-
sion (CR) underwent multiparametric flow cytometry
analysis on bone marrow samples every 3-6 months
to detect minimal residual disease (MRD). MRD de-
termination assays varied across all institutions, but
positive MRD was defined as .1% clonal CD5/
CD19 cells in the bone marrow.Time-to-event outcomes with competing risks
(ie, NRM and relapse rates) were estimated by cumu-
lative-incidence curves. Comparison of cumulative-
incidence curves was performed by the Lunn-McNeil
approach in which Cox regression analysis is applied
to competing risks [19]. OS and PFS were estimated
by the Kaplan-Meier method and compared using
the log-rank test. PFS estimates do not include
responses to DLI. Several factors were analyzed for
their association with OS, PFS, and NRM, including
age (50 years and younger versus.50 years), FISH ab-
normalities (unfavorable versus favorable), IgVH mu-
tation status (mutated versus unmutated), donor type
(sibling versus unrelated), status at transplantation
(progressive disease [PD] versus CR 1 partial remis-
sion [PR]), previous autologous transplantation, num-
ber of previous chemotherapy regimens (\3 versus 3
or more), alemtuzumab in the conditioning regimen,
and Flu refractoriness. Subsequently, multivariate
analysis according to the Cox proportional hazards
regression model was used to explore the indepen-
dent effect of variables that showed a significant
influence on OS or PFS by univariate analysis. In
all statistical calculations, a value of P \ .05 were
considered significant.
RESULTS
Patient Characteristics
Patients’ baseline characteristics were not signifi-
cantly different between cohorts, and are depicted in
Table 1. Median age at transplantation was 53 years
(range: 34-64), and 73% of patients were male. FISH
prognostic information was available in 38 patients
(61%); using the hierarchical model proposed by
Do¨hner et al. [20], 12 of them (32%) had 17p dele-
tion, 13 (34%) had 11q deletion, 4 (11%) had trisomy
12, and 9 (24%) did not have any detectable aberra-
tion. IgVH mutation status data was available in 35
patients (57%). Using the conventional 2% cutoff
level, 28 patients (80%) were classified as unmutated
CLL, while the remaining 7 patients had mutated
CLL. CD38 or ZAP-70 expression data were only
available in a small proportion of patients and there-
fore not considered. Two patients from cohort 1 ex-
perienced high-grade (Richter) transformation before
transplantation.
Transplantation took place at a median of 55
months after the initial CLL diagnosis (range: 5-132
months). Before the procedure, patients received a me-
dian of 3 chemotherapy regimens (range: 1-6). These
regimens varied across all 4 institutions, but 87% of
patients received Flu, 19% received alemtuzumab,
and 29% received rituximab before allo-HCT. Of 54
patients who received Flu prior to transplantation, 21
(39%) were considered refractory according to
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Cohort 1: Alemtuzumab +
CSP (n 5 41)
Cohort 2: CSP +
MTX or MMF (n 5 21)
P Value (Fisher’s Exact or
Mann-Whitney’s Test)
Age in years (median, range) 52 (37-64) 54 (34-64) .451
Sex (% male/female) 73/27 71/29 1.0
Unmutated IgVH genes (n, %) 15 (83%) 13 (77%) .691
Cytogenetics by FISH .495
17p deletion + 11q deletion (n, %) 14 (74%) 11 (58%)
Number of previous therapy lines (median, range) 3 (1-4) 3 (1-6) .620
Previous fludarabine (n, %) 37 (90%) 17 (81%) .426
Previous alemtuzumab (n, %) 7 (17%) 5 (24%) .520
Previous rituximab (n, %) 15 (37%) 3 (14%) .082
Prior autologous HCT (n, %) 7 (17%) 2 (10%) .705
Fludarabine refractoriness (n, %) 16 (43%) 5 (29%) .383
Months to first therapy (median, range) 1.5 (0-59) 4 (0-59) .429
Months to allogeneic HCT (median, range) 56 (5-105) 47 (11-132) .817
Disease status at HCT .054
Complete or partial remission (n, %) 35 (85%) 13 (62%)
Progressive disease (n, %) 6 (15%) 8 (38%)
Donor .639
Matched related (n, %) 32 (78%) 18 (86%)
Matched unrelated (n, %) 5 (12%) 1 (5%)
Mismatched unrelated (n, %) 4 (10%) 2 (9%)
CMV positive donor or recipient (n, %) 34 (83%) 19 (91%) .705
Follow-up from HCT (median, range) 38 (6-103) 59 (25-102) .066
CSP indicates cyclosporin; MTX, methotrexate; MMF, mycophenolate mofetil; IgVH, variable region of the immunoglobulin heavy-chain gene; FISH,
fluorescein in situ hybridization; HCT, hematopoietic cell transplantation; CMV, cytomegalovirus.National Cancer Institute (NCI) criteria [18]. Also, 9
patients (15%) had previously failed an autologous
HCT.
At the time of transplantation, 6 patients (10%)
were in complete remission, 42 (68%) were in partial
remission, and 14 (23%) had progressive CLL. There
was a trend toward a significantly higher proportion of
patients with progressive disease in cohort 2 (38%)
compared to cohort 1 (15%) (P 5 .054, Table 1).
Engraftment, Donor Chimerism, and GVDH
The graft source was PBSC for all patients. All but
1 patient had stable engraftment. The median interval
to neutrophil recovery (.0.5  109/L) was 14 days
(range: 10-36), and the median time to platelet recov-
ery (.20  109/L) was 12 days (range: 8-40). The
incidence of mixed chimerism at 6 months posttrans-
plantation was significantly higher in patients from
cohort 1 (43%) compared to patients from cohort 2
(11%) (P5 .03, Fisher’s exact test). However, the ma-
jority of these patients with mixed chimerism received
DLI and the global incidence of secondary graft failure
was 11% (95% confidence interval [CI], 3%-19%),
with no significant differences between cohorts (see
Table 2).
Grade II-IV aGVHD, including post-DLI
GVHD, was diagnosed in 15 patients (37%) from
cohort 1 and 12 patients (57%) from cohort 2 (P 5
.18). Severe (grade III-IV) aGVHD was observed in
8 (20%) and 8 (38%) patients from cohorts 1 and 2,
respectively (P 5 .14). Four patients (10%) from co-
hort 1 developed steroid-refractory GVHD compared
to 7 patients (33%) from cohort 2 (P 5 .03).cGVHD was documented in 12 (29%) and 13
(68%) patients from cohorts 1 and 2, respectively
(P 5 .016). Extensive cGVHD requiring systemic
therapy was observed in 4 patients (10%) from cohort
1 and 10 patients (48%) from cohort 2 (P 5 .03). As
a result, GVHD-related crude mortality was 10%
(1%-19%) for patients in cohort 1 and 33% (12%-
54%) for patients in cohort 2 (P 5 .034). Of all 10
patients with extensive cGVHD that are still alive, 6
are on immunosuppressive agents, 2 from cohort 1,
and 4 from cohort 2.
Infections
Severe infections were common in both cohorts,
with no significant differences between them (73%
versus 67%, P 5 .768, Table 3). Eleven patients
(18%) died of infectious complications, 7 of them
GVHD related. These infectious deaths were equally
distributed between cohorts (20% versus 14%,
P 5 .735), and comprised septicemia (4 patients),
EBV-related posttransplantation lymphoproliferative
disease (3 patients), bacterial pneumonia (1 patient),
bacterial meningitis (1 patient), pulmonary aspergillo-
sis (1 patient), and respiratory syncytial virus (RSV)
pneumonia (1 patient).
Globally, there was a trend toward a higher viral
infection rate in cohort 1 compared to cohort 2 (68%
versus 43%, P 5 .062). These were caused by herpes
simplex (7 patients), EBV (6 patients, including 3 post-
transplantation lymphoproliferative disorder [PTLD]
cases), adenovirus (5 patients), RSV (4 patients),
influenzae (3 patients), varicella zoster (2 patients),
metapneumovirus (1 patient), and parainfluenzae
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Cohort 1: Alemtuzumab +
CSP (n 5 41)
Cohort 2: CSP +
MTX or MMF (n 5 21)
P Value (Fisher’s Exact or
Mann-Whitney’s Test)
Primary engraftment failure (n, %) 1 (2%) 0 (0%) 1.0
Time to neutrophil recovery [>0.5  109/L] in days (median, range) 14 (10-27) 14 (13-36) .283
Time to platelet recovery [>20  109/L] in days (median, range) 12 (8-40) 13 (10-39) .132
Chimerism at 6 months (n, %) .030
Mixed 16 (43%) 2 (11%)
Full donor 21 (57%) 16 (89%)
Secondary engraftment failure (n, %) 5 (12%) 2 (9%) 1.0
NRM at 3 months (n, %) 0 (0%) 3 (14%) .035
NRM at 1 year (n, %) 8 (20%) 5 (24%) .748
NRM at 3 years (n, %) 11 (27%) 7 (33%) .768
Acute GVHD
Grace II-IV (n, %) 15 (37%) 12 (57%) .117
Grade III-IV (n, %) 8 (20%) 8 (38%) .135
Total (n, %) 21 (51%) 14 (67%) .288
Chronic GVHD
Extensive (n, %) 4 (10%) 10 (48%) .003
Total (n, %) 12 (29%) 13 (62%) .016
Steroid-refractory GVHD (n, %) 4 (10%) 7 (33%) .034
Cytomegalovirus reactivation (n, %) 21 (62%) 8 (42%) .250
Use of DLI (n, %) 20 (49%) 2 (10%) .002
CSP indicates cyclosporin; MTX, methotrexate; MMF, mycophenolate mofetil; NRM, nonrelapse mortality; GVHD, graft-versus-host disease; DLI, donor
lymphocyte infusions.(1 patient). Forty-nine patients (79%) were at risk of
CMV reactivation: 32 patients in cohort 1 and 17 pa-
tients in cohort 2. The incidence of CMV reactivation
was not significantly different between cohorts (66%
versus 47%, P 5 .237). There was a trend toward
a higher EBV reactivation rate, including 3 cases of
PTLD, in patients from cohort 1 (15% versus 0%, P
5 .088). Regarding fungal and bacterial infections,
they were equally distributed between cohorts (P 5
Table 3. Severe Infections According to Conditioning Regi-
men
Cohort 1:
Alemtuzumab +
CSP (n 5 41)
Cohort 2: CSP +
MTX or MMF
(n 5 21)
Viral
Cytomegalovirus
reactivation
21/32 (66%) 8/17 (47%)
Epstein-Barr
(reactivation or PTLD)
6 (15%) 0 (0%)
Respiratory syncytial 4 (10%) 0 (0%)
Adenovirus 5 (12%) 0 (0%)
Herpes simplex 5 (12%) 2 (10%)
Varicella zoster 1 (2%) 1 (5%)
Influenzae 2 (5%) 1 (5%)
Metapneumovirus 1 (2%) 0 (0%)
Parainfluenzae 1 (2%) 0 (0%)
Bacterial
Pseudomonas aeruginosa 2 (5%) 4 (19%)
Mycobacterium spp. 2 (5%) 0 (0%)
Nocardia asteroides 1 (2%) 0 (0%)
Campylobacter jejuni 0 (0%) 2 (10%)
Salmonella enterica 0 (0%) 1 (5%)
Escherichia coli 0 (0%) 2 (10%)
Klebsiella pneumoniae 0 (0%) 1 (5%)
Fungal
Aspergillus spp. 2 (5%) 2 (10%)
Pneumocystis jirovecci 1 (2%) 1 (5%)
CSP indicates cyclosporin; MTX, methotrexate; MMF, mycophenolate
mofetil; PTLD, posttransplant lymphoproliferative disorder..38 and P 5 1.0, respectively). The most commonly
isolated pathogens were Aspergillus spp. (4 patients)
and Pseudomonas aeruginosa (6 patients), and there
were 2 cases of Pneumocystis jirovecci pneumonia.
Disease Response, DLI, and Survival
The overall complete response rate among 56
patients with measurable disease at the time of trans-
plantation was 75% (64%-86%), whereas 18% (8%-
28%) had stable disease. Four patients (7%) were never
restaged after transplantation because of early death (3
patients) or unknown reasons (1 patient). The com-
plete response rate was 70% (55%-85%) for cohort 1
and 84% (68%-100%) for cohort 2 (P 5 .514).
Twenty-two patients (36%) received escalated
DLI: 20 patients (49%) from cohort 1 and 2 patients
(10%) from cohort 2 (P 5 .002). Reasons for DLI
were mixed chimerism in 9 patients, MRD in 5 pa-
tients, and residual or progressive CLL in 8 patients.
Of 9 patients with mixed chimerism, all but 1 achieved
full-donor chimerism, but 2 additional patients have
subsequently relapsed. Regarding patients with mini-
mal residual disease or clinical disease relapse, 6 pa-
tients responded to DLI, but only 2 are currently
free of disease.
With a median follow-up of 46 months (range:
6-103), 24 patients (39%) have died, 5 of progressive
disease, and 19 of transplant-related complications.
Cumulative incidences of NRM at 3 years were 28%
(17%-47%) for cohort 1 and 34% (18%-62%) for co-
hort 2, respectively (P 5 .735). Conversely, the 3-year
relapse rates were 32% (20%-52%) for cohort 1 and
20% (8%-47%) for cohort 2 (P 5 .112) (Figure 1).
Kaplan-Meier estimates of OS and PFS are shown in
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.112, respectively). Both outcomes were considered competing risks for the purpose of this analysis.Figure 2. Estimated OS and PFS rates at 3 years were
65% (49%-81%) and 39% (23%-55%), respectively,
for cohort 1 and 57% (35%-79%) and 47% (25%-
69%), respectively, for cohort 2. The log-statistic
showed no statistical differences (P 5 .629 for OS
and P5 .361 for PFS). The only variable with a signif-
icant impact onOSwas Flu refractoriness before trans-
plantation (P 5 .009, log-rank test).
DISCUSSION
The hematology community has recently wit-
nessed the appearance of several new agents, including
rituximab combinations [21], alemtuzumab [22],
ofatumumab [23], flavopiridol [24], or lenalidomide
[25] for young patients with relapsed or refractory
CLL. It is, however, uncertain at this time whether
these promising drugs will lead to prolonged survival
or not. In the past decade, multiple reports from
both sides of the Atlantic have suggested that RICallo-HCT may be a potentially curative strategy for
these patients [12,14,26-30]. The aim of this approach
is to deliver the advantages of the GVL effect without
the NRM associated with conventional allo-HCT
[11]. Recently, the European Group of Blood and
Marrow Transplantation (EBMT) has recently pub-
lished a set of guidelines suggesting situations where
allo-HCT might be considered a therapeutic option
for CLL patients. Their conclusion was that allo-
HCTwas reasonable for younger CLL patients refrac-
tory to Flu, failing autologous HCT, or with p53
abnormalities requiring treatment [10].
Once a patient is considered a suitable candidate
for allo-HCT, the next important decision is the
type of conditioning regimen to use. The EBMT
Consensus Group suggested that RIC allo-HCT is
effective for poor-risk CLL, regardless of its compari-
son to conventional myeloablative allo-HCT [10]. In
addition, a recent retrospective comparison from the
Seattle Group revealed that CLL and lymphoma
patients with comorbidities, whether young or old,Figure 2. OS (A) and PFS (B) according to conditioning regimen (with alemtuzumab, gray line; without alemtuzumab, black line; P 5 .629 and .361,
respectively).
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tional allo-HCT. The same study also showed that
the conditioning regimen only played a minor role in
terms of disease control [30]. There is, however, con-
siderable controversy regarding the potential benefit
of T cell depletion (TCD), either with alemtuzumab
or other methods. For instance, a recent multicenter
randomized trial assessed the impact of TCD by phys-
ical and immunologic methods on unrelated donor
bone marrow transplantation. Interestingly, the
3-year disease-free survival (DFS) was similar for
both TCD and non-TCD allografts, whereas aGVHD
rates were significantly lower for patients receiving
TCD grafts. Relapse rates were not adversely affected
by TCD, with the only exception of patients with
chronic myelogenous leukemia (CML). The conclu-
sion of this study was that TCD did not enhance
patient survival despite reducing GVHD rates and
early toxicity [31].
We therefore decided to compare retrospectively
the results obtained in patients with poor-risk CLL
undergoing RIC allo-HCT with or without alemtuzu-
mab. One of the strengths of this study is the reduced
number of participant centers, which was specifically
sought after to avoid the center effect. The center ef-
fect has long been recognized as a very important vari-
able for patients undergoing allo-HCT for acute
myelogenous leukemia (AML) [32]. In CLL, we had
previously observed a potential center effect in patients
undergoing RIC allo-HCT [14], and therefore de-
cided to select 2 transplant centers from Spain and 2
from the UK. All 4 institutions have performed a sig-
nificant number of procedures in this group of patients
and have similar NRM rates. In addition, all patients
were conditioned with a Flu plus Mel regimen, with
or without alemtuzumab.
In concordance with a previous similar study
including all types of lymphoid malignancies [33],
this analysis confirms that alemtuzumab significantly
reduces the cGVHD and steroid-refractory GVHD
rates, as well as the GVHD-related mortality. There
was also a trend toward a reduction in grade II-IV
aGVHD. The low GVHD rates detected in cohort 1
are consistent with previous reports using alemtuzu-
mab [14]. Also, the cGVHD rates obtained in cohort
2 is very similar to those observed in other centers
[28], and almost identical to the results obtained by
the Spanish Cooperative Group using the same condi-
tioning regimen in patients with AML [34]. These
facts make us believe that this difference in GVHD
rates observed in our study is genuine. This reduced
GVHD rate was, however, partially offset by a trend
toward an increased relapse rate for patients receiving
alemtuzumab, which did not translate into a signifi-
cantly worse PFS or OS. This contrasts with the out-
comes achieved with RIC allo-HCT in multiple
myeloma (MM) or CML, where the addition of alem-tuzumab or any T cell-depleting agent is potentially
detrimental [31,33,35,36]. It is, however, remarkable
that no patient from cohort 2 has relapsed later than
3 years after HCT, whereas a number of late relapses
have been observed in cohort 1. Perhaps, a similar
study with more patients would have shown a signifi-
cantly different PFS between cohorts [33].
This analysis has also shown that CLLmay be sus-
ceptible to GVL effect [37]. The incidence of mixed
chimerism after transplantation was significantly
higher in patients from cohort 1. DLI were almost ex-
clusively given to patients from cohort 1 and were very
effective for transforming mixed chimerism into com-
plete donor chimerism. DLI were nevertheless less ef-
fective for relapsed or progressive disease. Even
though 6 of 13 patients (46%) who received escalated
DLI for MRD or clinical progression initially re-
sponded to the measure, only 3 patients (23%) are cur-
rently free of CLL. These results confirm previous
reports showing response rates around 15% for CLL
patients receiving DLI for relapsed disease after
HCT [28,38-40]. In contrast, theMDAnderson group
has recently reported response rates toDLI in excess of
50% for patients with progressive CLL following RIC
allo-HCT, but interpretation of their studies is
complicated by the concomitant administration of
rituximab [41].
Infections were frequent, and contributed to a sig-
nificant proportion of deaths and morbidity. However,
patients from cohort 1 did not experience increased
CMV reactivation rates compared to patients from
cohort 2, in contrast to previous studies [33]. We be-
lieve this is because of the fact that poor-risk CLL
patients are intrinsically prone to infections regardless
of the conditioning regimen received. This suscepti-
bility to infections is disease and therapy related, and
is secondary to multiple factors, including hypogam-
maglobulinemia, defective T and natural killer (NK)
cell function, neutropenia, and deficient complement
activity [42]. Indeed, it is widely acknowledged that in-
fections account for up to 50% of all CLL-related
deaths [15,43]. Furthermore, alemtuzumab depletes
incoming T cells and delays the immune reconstitu-
tion after allo-HCT. However, we hypothesize that
the detrimental effect of alemtuzumab in cohort 1
was counterbalanced by the greater risk of extensive
cGVHD observed in cohort 2. This increased
GVHD rate led to the administration of systemic cor-
ticosteroids or very potent immunosuppressive agents,
such as inolimomab or daclizumab, which may have
compromised their immune reconstitution even
further.
A major concern about the use of TCD in allo-
HCT is the increased incidence of EBV-related
PTLD. Several studies have concluded that the risk
of PTLD depends greatly on the method of TCD
used, being considerably higher for specific T cell
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cell antibodies (eg, alemtuzumab) [44]. In this study,
3 patients from cohort 1 developed PTLD, which
was also their cause of death. This prompted a strict
virologic surveillance by means of quantitative PCR
for all patients receiving alemtuzumab as part of their
conditioning regimen, and 3 further patients were
noted to have EBV reactivation. Preemptive adminis-
tration of rituximab in these 3 patients was sufficient
to prevent the development of PTLD.
As previously reported [14], secondary graft failure
was observed in a significant proportion of patients
from both cohorts (12% versus 9%, P5 1.0).We spec-
ulate that this phenomenon is disease related, as there
is some evidence that sustained allogeneic engraftment
is mediated by host dendritic cells, which are seriously
defective in CLL patients [45]. As a matter of fact, a re-
cent report on unrelated transplantation for CLL us-
ing myeloablative conditioning regimens revealed an
even higher incidence (18%) of graft failure [46].
Flu refractoriness confirmed its significant impact
on OS as previously observed [14]. Several other
groups have analyzed the effect of response to prior
chemotherapy, particularly Flu, as a major prognostic
factor for patients undergoing allo-HCT. The MD
Anderson and other groups have recently published
updated results showing that chemorefractoriness at
the time of transplantation is a very important predic-
tive factor in terms or disease relapse and survival
[29,41]. In our series, Flu refractory patients had a me-
dian OS of 17 months following allo-HCT, which is
still insufficient and marginally better than historic re-
sults obtained with conventional chemotherapy (10
months) or alemtuzumab (16 months) as salvage ther-
apy [47,48]. Alternative therapies or transplantation
regimens are clearly needed for these patients. For
the time being, we would favor the use of alemtuzumab
in patients receiving their grafts from unrelated do-
nors, particularly if they are mismatched, unless there
is a very high relapse risk (eg, patients with chemore-
fractory disease at transplantation). For the remaining
patients the jury is still out, and we would base our rec-
ommendation on physician’s preference, the availabil-
ity of cells for DLI, molecular techniques for CMV
and EBV detection, and so forth.
We would like to acknowledge that the conclu-
sions drawn from this retrospective analysis are less
compelling than those from randomized prospective
studies. However, in the absence of prospective ran-
domized trials requiring multicenter collaboration,
retrospective analyses may provide adequate data to
continue improving our clinical practice. Another
weakness of the study is the diverse alemtuzumab
dose received by patients from cohort 1, as many
patients were recruited in the Campath De-escalation
Protocol. This trial has recently completed its recruit-
ment, and will try to establish the alemtuzumab dosethat provides the best GVHD protection with the low-
est relapse rate. Unfortunately, low patient numbers
did not allow us to evaluate the impact of each alemtu-
zumab dose on NRM, GVHD rates, and survival, and
this will be the subject of future publications including
the whole cohort. Finally, it could be argued that the
statistical power of the study was suboptimal as cohort
1 included only 21 patients. After much consideration,
we decided that it was better to have a small cohort of
patients receiving the same conditioning regimen at 2
experienced institutions rather than a more heteroge-
nous cohort receiving diverse regimens at many differ-
ent institutions.
In conclusion, results with RIC allo-HCT are
promising for these poor-prognosis patients. Both
conditioning regimens provided similar NRM, PFS,
and OS. Furthermore, the alemtuzumab-based regi-
men was effective in reducing the cGVHD rate but
was associated with a trend toward an increased
relapsed rate. Infection rates were similarly high for
both cohorts and contributed to a significant propor-
tion of morbidity and mortality.
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